Agonistic monoclonal antibodies
Apr 04, 2019
AgomAb Therapeutics raises $23.5M; Allergan’s eye drug; Good news for the patients; Dyne Therapeutics comes to life
AgomAb Therapeutics raises USD 23.5 million for its agomAbs A Belgian biotherapeutics company AgomAb Therapeutics which has been in a long run of making agonistic antibodies has secured USD 23.5 million in a Series A financing round from international investor syndicate co-led by V-Bio Ventures (Belgium) and Adv...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
